Real world outcome of high|risk multiple myeloma

Real World Outcome of High-Risk Multiple Myeloma - PubMed

Introduction: High risk myeloma is heterogeneous with significant variation in risk stratifications. Real world outcomes differ from controlled ...

Real world outcome of high-risk multiple myeloma - ScienceDirect.com

This study from an Indian tertiary care set up highlights' treatment patterns and outcome of real-world high risk myeloma patients. Out of 384, ...

Impact of Ultra High-risk Genetics on Real-world Outcomes of ...

Refined prediction of early relapse following standard-of-care (SoC) autologous stem cell transplant (ASCT) in newly diagnosed multiple myeloma (NDMM) could ...

Navigating High-Risk and Ultrahigh-Risk Multiple Myeloma

Therapeutic advances have led to unprecedented survival outcomes in multiple myeloma (MM), and young newly diagnosed patients now experience ...

Impact of Ultra High-risk Genetics on Real-world Outcomes...

Refined prediction of early relapse following standard-of-care (SoC) autologous stem cell transplant (ASCT) in newly diagnosed multiple myeloma (NDMM) could ...

Study Finds Huge Gap Between Clinical Trial Data and Real-World ...

Patients treated in real-world settings for multiple myeloma had death rates 75% higher than those in clinical trials, according to data from a 13-year period.

Real-world outcomes of tandem ASCT in newly diagnosed multiple ...

During the specified period, 66 NDMM patients underwent ASCT in our center. Of these, 11 (16.6%) with high-risk cytogenetic features were ...

Worse Outcomes for Myeloma Patients in Real-World Vs. Trials

In the real world, multiple myeloma patients demonstrated a 44% reduction in progression-free survival (PFS) and a 75% decrease in overall ...

Real-world treatment patterns and outcomes in relapsed/refractory ...

In the context of multiple myeloma (MM), early use of the immunomodulatory drug lenalidomide has led to an increased population of patients ...

Real-world assessment of the treatment patterns and outcomes ...

The worldwide incidence of multiple myeloma (MM), a plasma cell neoplasm, was estimated to be 176,000 cases, with an estimated mortality in ...

Real-world multiple myeloma risk factors and outcomes by non ...

71 years) and more likely to be female (53.4% vs. 43.5%). Rates of high-risk cytogenetics and 1q21+ were similar between races/ethnicities. The most common ...

Real world evidence of epidemiological trends, clinical presentation ...

Results: During the study period of 15 years, a total of 192 patients were diagnosed with MM. The incident rate of myeloma cases in 2021 was 8 patients per ...

Real-World Outcomes of High-Risk Multiple Myeloma

Patients who received transplantation were only 34.6% of the patients in the standard treatment. Patients with high-risk MM who receive ...

Paper: Real-World Treatment Patterns and Outcomes of Patients ...

Revised International Staging System is used to identify patients with high-risk MM, however a better definition of high risk includes “ ...

Real-world Outcomes in Multiple Myeloma | Cancer Today

The pooled results found that real-world patients with multiple myeloma had 44% worse progression-free survival, which refers to the time from ...

Daratumumab-Based Therapeutic Approaches and Clinical ...

We identified an ultra-high-risk subgroup of patients with primary refractory disease, of whom 90% harboured high-risk FISH abnormalities, and ...

Real-world prognostic significance of attaining minimal residual ...

Our results showed that compared to standard-risk myeloma patients with MRD negativity, high-risk myeloma patients with MRD negativity showed ...

Navigating High-Risk and Ultrahigh-Risk Multiple Myeloma

High- and Ultrahigh-Risk Myeloma. Page 14. REFERENCES. 1. Cote J, Leblanc R, Chu MP, et al: Real-world results of autologous stem cell ...

High-risk disease in newly diagnosed multiple myeloma - Nature

Multiple myeloma (MM) is an acquired malignant plasma cell disorder that develops late in life. Although progression free and overall ...

Recap: Recent Advances in Multiple Myeloma: Applying Real-world ...

At the time the data were published, the median overall survival (OS) was 78.2 months (95% CI, 62.2-94.2) for high-risk patients and had not ...